For the quarter ending 2026-03-31, TPST had -$5,902K decrease in cash & cash equivalents over the period. -$7,598K in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -27,696 | -4,021 | -3,511 | -18,730 |
| Depreciation expense | 60 | 65 | 66 | 135 |
| Stock-based compensation expense | 226 | 576 | 61 | 2,481 |
| Non-cash lease expense | 292 | 285 | 279 | 539 |
| Non-cash interest and other expense, net | 0 | 8 | 1 | 76 |
| Acquired in-process research and development | 19,927 | - | - | - |
| Prepaid expenses and other assets | 71 | -33 | -243 | -339 |
| Accounts payable | -454 | 116 | -3,794 | 2,266 |
| Accrued expenses and other liabilities | 405 | -372 | 134 | -3,166 |
| Interest payable | 0 | 0 | 0 | -59 |
| Operating lease liabilities | -287 | -264 | -258 | -348 |
| Cash used in operating activities | -7,598 | -3,574 | -6,779 | -16,467 |
| Purchase of property and equipment | 0 | 0 | 0 | 0 |
| Cash used in investing activities | 0 | 0 | 0 | 0 |
| Proceeds from the issuance of common stock, net of issuance costs | - | 1,032 | 0 | 5,013 |
| Proceeds from the issuance of pre-funded warrants, net of issuance costs | - | 1,451 | 0 | 1,858 |
| Proceeds from issuance of common stock, pre-funded warrants and common stock warrants, net of issuance costs | 1,272 | - | - | - |
| Proceeds from the issuance of common stock warrants, net of issuance costs | - | 1,284 | - | - |
| Proceeds from issuance of common stock and common stock warrants to related party net of issuance costs | 424 | - | - | - |
| Repayment of loan | 0 | 0 | 0 | 6,426 |
| Proceeds from the issuance of common stock under equity plan awards | 0 | 0 | 13 | 34 |
| Cash provided by (used in) financing activities | 1,696 | 3,767 | 13 | 479 |
| Net decrease in cash, cash equivalents and restricted cash | -5,902 | 193 | -6,766 | -15,988 |
| Cash, cash equivalents and restricted cash at beginning of period | 8,150 | 7,957 | 30,711 | - |
| Cash, cash equivalents and restricted cash at end of period | 2,248 | 8,150 | 7,957 | - |
Tempest Therapeutics, Inc. (TPST)
Tempest Therapeutics, Inc. (TPST)